Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 9143
Country/Region: Kenya
Year: 2015
Main Partner: Henry M. Jackson Foundation for the Advancement of Military Medicine
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $2,038,786 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $310,199
Care: Orphans and Vulnerable Children (HKID) $11,322
Care: TB/HIV (HVTB) $101,834
Care: Pediatric Care and Support (PDCS) $46,258
Strategic Information (HVSI) $335,000
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $32,000
Prevention: HIV Testing and Counseling (HVCT) $59,553
Sexual Prevention: Other Sexual Prevention (HVOP) $273,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $62,528
Treatment: Adult Treatment (HTXS) $720,361
Treatment: Pediatric Treatment (PDTX) $86,731
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR_DSD Age/sex: 1-4 Female 2016 22
CARE_CURR_DSD Age/sex: 1-4 Male 2016 23
CARE_CURR_DSD Age/sex: 10-14 Female 2016 32
CARE_CURR_DSD Age/sex: 10-14 Male 2016 33
CARE_CURR_DSD Age/sex: 15-19 Female 2016 44
CARE_CURR_DSD Age/sex: 15-19 Male 2016 28
CARE_CURR_DSD Age/sex: 20-24 Female 2016 143
CARE_CURR_DSD Age/sex: 20-24 Male 2016 46
CARE_CURR_DSD Age/sex: 25-49 Female 2016 1,338
CARE_CURR_DSD Age/sex: 25-49 Male 2016 1,119
CARE_CURR_DSD Age/sex: 5-9 Female 2016 41
CARE_CURR_DSD Age/sex: 5-9 Male 2016 42
CARE_CURR_DSD Age/sex: 50+ Female 2016 105
CARE_CURR_DSD Age/sex: 50+ Male 2016 463
CARE_CURR_DSD Age/sex: <1 Female 2016 4
CARE_CURR_DSD Age/sex: <1 Male 2016 4
CARE_CURR_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 1,630
CARE_CURR_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 1,656
CARE_CURR_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 99
CARE_CURR_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 102
CARE_CURR_DSD Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 3,487
CARE_CURR_DSD Sum of Age/Sex disaggregates 2016 3,487
CARE_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2016 3,487
CARE_NEW_DSD Age/sex: 1-4 Female 2016 2
CARE_NEW_DSD Age/sex: 1-4 Male 2016 3
CARE_NEW_DSD Age/sex: 10-14 Female 2016 3
CARE_NEW_DSD Age/sex: 10-14 Male 2016 3
CARE_NEW_DSD Age/sex: 15-19 Female 2016 3
CARE_NEW_DSD Age/sex: 15-19 Male 2016 2
CARE_NEW_DSD Age/sex: 20-24 Female 2016 9
CARE_NEW_DSD Age/sex: 20-24 Male 2016 1
CARE_NEW_DSD Age/sex: 25-49 Female 2016 87
CARE_NEW_DSD Age/sex: 25-49 Male 2016 72
CARE_NEW_DSD Age/sex: 5-9 Female 2016 4
CARE_NEW_DSD Age/sex: 5-9 Male 2016 5
CARE_NEW_DSD Age/sex: 50+ Female 2016 6
CARE_NEW_DSD Age/sex: 50+ Male 2016 30
CARE_NEW_DSD Age/sex: <1 Male 2016 1
CARE_NEW_DSD Aggregated Age/sex: 15+ Female 2016 105
CARE_NEW_DSD Aggregated Age/sex: 15+ Male 2016 105
CARE_NEW_DSD Aggregated Age/sex: <15 Female 2016 9
CARE_NEW_DSD Aggregated Age/sex: <15 Male 2016 12
CARE_NEW_DSD Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 231
CARE_NEW_DSD Sum of Age/sex disaggregates 2016 231
CARE_NEW_DSD Sum of Aggregated Age/sex disaggregates 2016 231
FPINT_SITE_DSD Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2016 14
FPINT_SITE_DSD Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment 2016 14
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 8,514
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 8,540
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 763
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 794
HTC_TST_DSD By Test Result: Negative 2016 18,421
HTC_TST_DSD By Test Result: Positive 2016 190
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 18,611
HTC_TST_DSD Sum of Aggregated Age/Sex 15+ 2016 17,054
HTC_TST_DSD Sum of Aggregated Age/Sex <15 2016 1,557
HTC_TST_DSD Sum of Aggregated Age/Sex disaggregates 2016 18,611
HTC_TST_DSD Sum of Test Result disaggregates 2016 18,611
OVC_ACC_DSD Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services 2016 276
OVC_SERV_DSD Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2016 276
PMTCT_ARV_DSD Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 130
PMTCT_ARV_DSD Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 130
PMTCT_ARV_DSD Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 56
PMTCT_ARV_DSD Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 74
PMTCT_ARV_DSD Sum of New and Current disaggregates 2016 130
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2016 111
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2016 6
PMTCT_EID_DSD Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 117
PMTCT_EID_DSD Sum of Infant Age disaggregates 2016 117
PMTCT_STAT_DSD By: Known positives at entry 2016 65
PMTCT_STAT_DSD By: Number of new positives identified 2016 65
PMTCT_STAT_DSD Number of new ANC and L&D clients 2016 3,420
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 3,355
PMTCT_STAT_DSD Sum of Positives Status disaggregates 2016 130
PP_PREV_DSD Age/sex: 10-14 Female 2016 931
PP_PREV_DSD Age/sex: 10-14 Male 2016 1,115
PP_PREV_DSD Age/sex: 15-19 Female 2016 478
PP_PREV_DSD Age/sex: 15-19 Male 2016 402
PP_PREV_DSD Age/sex: 20-24 Female 2016 1,690
PP_PREV_DSD Age/sex: 20-24 Male 2016 1,239
PP_PREV_DSD Age/sex: 25-49 Female 2016 14,030
PP_PREV_DSD Age/sex: 25-49 Male 2016 12,051
PP_PREV_DSD Age/sex: 50+ Female 2016 1,750
PP_PREV_DSD Age/sex: 50+ Male 2016 5,314
PP_PREV_DSD Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 39,000
PP_PREV_DSD Sum of Age/Sex disaggregates 2016 39,000
PP_PREV_DSD Total number of people in the target population 2016 135,000
TB_ART_DSD Aggregated Age: 15+ 2016 14
TB_ART_DSD Aggregated Age: <15 2016 3
TB_ART_DSD Female 2016 8
TB_ART_DSD Known HIV-positive 2016 10
TB_ART_DSD Male 2016 9
TB_ART_DSD Sum of Aggregated Age disaggregates 2016 17
TB_ART_DSD Sum of Sex disaggregates 2016 17
TB_ART_DSD Sum of Test Status disaggregates 2016 10
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 57
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 17
TB_SCREEN_DSD Age: 1-4 2016 87
TB_SCREEN_DSD Age: 10-14 2016 165
TB_SCREEN_DSD Age: 15-19 2016 63
TB_SCREEN_DSD Age: 5-9 2016 111
TB_SCREEN_DSD Age: <1 2016 14
TB_SCREEN_DSD Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2016 2,761
TB_SCREEN_DSD Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2016 377
TB_SCREEN_DSD Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 3,487
TB_SCREEN_DSD Sex: Female 2016 1,565
TB_SCREEN_DSD Sex: Male 2016 1,573
TB_SCREEN_DSD Sum of Age disaggregates 2016 3,138
TB_SCREEN_DSD Sum of Aggregated Age disaggregates 2016 3,138
TB_SCREEN_DSD Sum of Sex disaggregates 2016 3,138
TB_SCREEN_DSD The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 3,138
TX_CURR_DSD Age/Sex: 1-4 Female 2016 22
TX_CURR_DSD Age/Sex: 1-4 Male 2016 22
TX_CURR_DSD Age/Sex: 5-14 Female 2016 41
TX_CURR_DSD Age/Sex: 5-14 Male 2016 42
TX_CURR_DSD Age/Sex: <1 Female 2016 4
TX_CURR_DSD Age/Sex: <1 Male 2016 4
TX_CURR_DSD Aggregated Age/Sex: 15+ Female 2016 1,554
TX_CURR_DSD Aggregated Age/Sex: 15+ Male 2016 1,561
TX_CURR_DSD Aggregated Age/Sex: <1 Female 2016 4
TX_CURR_DSD Aggregated Age/Sex: <1 Male 2016 4
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2016 3,342
TX_CURR_DSD Sum of age/sex disaggregates 2016 3,342
TX_CURR_DSD Sum of Aggregated Age/Sex (<1 and 1-14) <15 2016 125
TX_CURR_DSD Sum of Aggregated Age/Sex 15+ 2016 3,115
TX_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2016 3,115
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Female 2016 319
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Male 2016 333
TX_NEW_DSD By Age/Sex: 1-4 Female 2016 2
TX_NEW_DSD By Age/Sex: 1-4 Male 2016 2
TX_NEW_DSD By Age/Sex: 10-14 Female 2016 3
TX_NEW_DSD By Age/Sex: 10-14 Male 2016 3
TX_NEW_DSD By Age/Sex: 15-19 Female 2016 8
TX_NEW_DSD By Age/Sex: 15-19 Male 2016 6
TX_NEW_DSD By Age/Sex: 20-24 Female 2016 29
TX_NEW_DSD By Age/Sex: 20-24 Male 2016 6
TX_NEW_DSD By Age/Sex: 25-49 Female 2016 285
TX_NEW_DSD By Age/Sex: 25-49 Male 2016 230
TX_NEW_DSD By Age/Sex: 5-9 Female 2016 6
TX_NEW_DSD By Age/Sex: 5-9 Male 2016 6
TX_NEW_DSD By Age/Sex: 50+ Female 2016 25
TX_NEW_DSD By Age/Sex: 50+ Male 2016 104
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 715
TX_NEW_DSD Pregnancy status 2016 70
TX_NEW_DSD Sum of Age/Sex disaggregates 2016 715
TX_NEW_DSD Sum of Aggregated Age/Sex disaggregates 2016 652
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 406
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 670
VMMC_AE_DSD Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2016 1
VMMC_CIRC_DSD By Age: 1-9 2016 17
VMMC_CIRC_DSD By Age: 10-14 2016 16
VMMC_CIRC_DSD By Age: 15-19 2016 46
VMMC_CIRC_DSD By Age: 20-24 2016 236
VMMC_CIRC_DSD By Age: 50+ 2016 15
VMMC_CIRC_DSD By Age: <1 2016 1
VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 2016 500
VMMC_CIRC_DSD By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2016 50
VMMC_CIRC_DSD By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2016 450
VMMC_CIRC_DSD By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2016 495
VMMC_CIRC_DSD By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2016 5
VMMC_CIRC_DSD Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2016 500
VMMC_CIRC_DSD Sum of age disaggregates 2016 331
Cross Cutting Budget Categories and Known Amounts Total: $40,000
Food and Nutrition: Commodities $30,000
Gender: Gender Based Violence (GBV) $2,000
Post GBV Care
Capacity building
Education $8,000